Vedolizumab in the therapy of ulcerative colitis patients

Czech version

Authors: M. Lukáš
Authors‘ workplace: Klinické a výzkumné centrum pro idiopatické střevní záněty ISCARE I. V. F. a. s. a 1. LF UK v Praze
Published in: Gastroent Hepatol 2015; 69(1): 29-32
Category: IBD: Review Article
doi: https://doi.org/10.14735/amgh201529

Overview

Vedolizumab is a monoclonal IgG1 antibody, which has been approved to use in clinical practice for ulcerative colitis patients in Europan Union a few months ago. There is a big expectation on availability of vedolizumab at the market in Czech Republic in these year. The clinical research named GEMINI I proved that vedolizumab is a very effective drug in patients with moderate to severe ulcerative colitis. The significant advantages of vedolizumab therapy is a high efficacy in those patients who failed to anti‑TNFα therapy, sustained response due to maintenance therapy with arising effect over time, a minimal drug’s immunogenicity and highly safety drug’s profile, which is caused by a high selectivity for gastrointestinal tract. There are some disadvantages or uncertainty which include slow antiinflammatory therapeutic response, restricted effect on extraintestinal manifestations.

Key words:
vedolizumab – ulcerative colitis – biological therapy

Autor deklaruje, že v souvislosti s předmětem studie nemá žádné komerční zájmy.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
12. 1. 2015

Accepted:
9. 2. 2015

Sources

1. Bortlík M. Vedolizumab – nová antiintegrinová protilátka s vysokou gastrointestinální selektivitou. Gastroent Hepatol 2014; 68(6): 481– 484. doi: 10.14735/ amgh 2014481.

2. Raine T. Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterol J 2014; 2(5): 333– 344. doi: 10.1177/ 2050640614550672.

3. Feagan BG, Rutgeerts P, Sands BE et al.Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369(8): 699– 710. doi: 10.1056/ NEJMoa1215734.

4. Lukáš M. Biologická léčba idiopatických střevních zánětů. In: Pavelka K, Arenberger P, Lukáš M et al (eds). Biologická léčba zánětlivých autoimunitních onemocnění v revmatologii, dermatologii a gastroenterologii. Praha: Grada 2014.

5. Lukáš M. Současnost a budoucnost v léčbě ulcerózní kolitidy.Gastroent Hepatol 2013; 67(3): 212– 218.